EBITDA: Income before interest, taxes, depreciation and amortization.
AbCellera Biologics Inc. (ABCL) had EBITDA of $-188.28M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$75.13M |
|
$-146.41M |
|
-- |
|
$75.13M |
|
$292.23M |
|
$-217.10M |
|
$39.51M |
|
$-177.59M |
|
$-177.59M |
|
$-146.41M |
|
$-146.41M |
|
$-146.41M |
|
$-146.41M |
|
$-217.10M |
|
|
EBITDA |
$-188.28M |
298.71M |
|
298.71M |
|
$-0.49 |
|
$-0.49 |
|
| Balance Sheet Financials | |
$728.23M |
|
$428.00M |
|
$628.72M |
|
$1.36B |
|
$64.31M |
|
-- |
|
$325.74M |
|
$390.05M |
|
$966.90M |
|
$880.72M |
|
$966.90M |
|
300.60M |
|
| Cash Flow Statement Financials | |
$-131.29M |
|
$87.75M |
|
$14.08M |
|
$183.62M |
|
$155.25M |
|
$-28.37M |
|
$55.79M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
11.32 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-288.98% |
|
-288.98% |
|
-250.62% |
|
-236.39% |
|
-194.88% |
|
$-174.07M |
|
-- |
|
-- |
|
-- |
|
0.06 |
|
-- |
|
1.29 |
|
283.21 |
|
-15.14% |
|
-16.62% |
|
-10.79% |
|
-15.14% |
|
$3.22 |
|
$-0.58 |
|
$-0.44 |
|